Caplacizumab in the Treatment of Thrombotic Thrombocytopenic Purpura: A Systematic Review and Meta-Analysis of Observational Studies

Introduction: Thrombotic Thrombocytopenic Purpura (TTP) is an uncommon thrombotic disorder characterized by the formation of platelet-rich microthrombi due to a reduction in ADAMTS13 levels. Caplacizumab has surfaced as a viable therapeutic alternative. Consequently, we conducted a thorough review a...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2024-11, Vol.144, p.5450-5450
Main Authors: Khan, Salman, Karmani, Vikash Kumar, Ali, Aizaz, Khan, Malik W.Z., Ahmad, Muhammad, Niazi, Muhammad, Qandil, Hamzah, Yetiskul, Ekrem, Khamis, Zaid, Araji, Ghada, Sarkis, Tyler, Mohan, Preet, Afif, Sarah
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: Thrombotic Thrombocytopenic Purpura (TTP) is an uncommon thrombotic disorder characterized by the formation of platelet-rich microthrombi due to a reduction in ADAMTS13 levels. Caplacizumab has surfaced as a viable therapeutic alternative. Consequently, we conducted a thorough review and meta-analysis to evaluate caplacizumab in the management of TTP. Method: We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines, searching PubMed, Google Scholar, and Cochrane CENTRAL databases from inception to December 2023. The evaluated outcomes included Time to normalization of platelet count, Days of Plasma Exchange, Length of Hospitalization, Relapses, Exacerbations, and Refractory Disease. Additionally, we included patients who had undergone at least one therapeutic plasma exchange. The Review Manager software was utilized to perform the meta-analysis, wherein risk ratios (RR) were calculated, 95% confidence intervals were ascertained, and statistical significance was established as a p-value
ISSN:0006-4971
DOI:10.1182/blood-2024-201087